Literature DB >> 21193869

The relevance of assessment of intestinal P-gp inhibition using digoxin as an in vivo probe substrate.

Jack G Shi, Yan Zhang, Swamy Yeleswaram.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21193869     DOI： 10.1038/nrd3028-c1

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN： 1474-1776            Impact factor:   84.694


× No keyword cloud information.
  13 in total

Review 1.  Membrane transporters in drug development.

Authors:  Kathleen M Giacomini; Shiew-Mei Huang; Donald J Tweedie; Leslie Z Benet; Kim L R Brouwer; Xiaoyan Chu; Amber Dahlin; Raymond Evers; Volker Fischer; Kathleen M Hillgren; Keith A Hoffmaster; Toshihisa Ishikawa; Dietrich Keppler; Richard B Kim; Caroline A Lee; Mikko Niemi; Joseph W Polli; Yuichi Sugiyama; Peter W Swaan; Joseph A Ware; Stephen H Wright; Sook Wah Yee; Maciej J Zamek-Gliszczynski; Lei Zhang
Journal:  Nat Rev Drug Discov       Date:  2010-03       Impact factor: 84.694

2.  Correlation of digoxin-tablet dissolution-rate with biological availability.

Authors:  P Reissell; K Ojala; V Manninen; A Sothman
Journal:  Br J Clin Pharmacol       Date:  1977-04       Impact factor: 4.335

3.  Absorption of orally given digoxin preparations.

Authors:  D H Huffman; D L Azarnoff
Journal:  JAMA       Date:  1972-11-20       Impact factor: 56.272

4.  Disposition and bioavailability of the beta 1-adrenoceptor antagonist talinolol in man.

Authors:  B Trausch; R Oertel; K Richter; T Gramatté
Journal:  Biopharm Drug Dispos       Date:  1995-07       Impact factor: 1.627

5.  Evidence for intestinal secretion as an additional clearance pathway of talinolol enantiomers: concentration- and dose-dependent absorption in vitro and in vivo.

Authors:  U Wetterich; H Spahn-Langguth; E Mutschler; B Terhaag; W Rösch; P Langguth
Journal:  Pharm Res       Date:  1996-04       Impact factor: 4.200

6.  Induction of P-glycoprotein by rifampin increases intestinal secretion of talinolol in human beings: a new type of drug/drug interaction.

Authors:  K Westphal; A Weinbrenner; M Zschiesche; G Franke; M Knoke; R Oertel; P Fritz; O von Richter; R Warzok; T Hachenberg; H M Kauffmann; D Schrenk; B Terhaag; H K Kroemer; W Siegmund
Journal:  Clin Pharmacol Ther       Date:  2000-10       Impact factor: 6.875

7.  Effects of controlled-release on the pharmacokinetics and absorption characteristics of a compound undergoing intestinal efflux in humans.

Authors:  Marija Tubic; Daniel Wagner; Hildegard Spahn-Langguth; Christine Weiler; Roland Wanitschke; Wulf Otto Böcher; Peter Langguth
Journal:  Eur J Pharm Sci       Date:  2006-04-26       Impact factor: 4.384

8.  Effect of grapefruit juice on digoxin pharmacokinetics in humans.

Authors:  L Becquemont; C Verstuyft; R Kerb; U Brinkmann; M Lebot; P Jaillon; C Funck-Brentano
Journal:  Clin Pharmacol Ther       Date:  2001-10       Impact factor: 6.875

9.  Pharmacokinetic and pharmaceutic interaction between digoxin and Cremophor RH40.

Authors:  Yorki Tayrouz; Reinhard Ding; Jürgen Burhenne; Klaus-Dieter Riedel; Johanna Weiss; Torsten Hoppe-Tichy; Walter Emil Haefeli; Gerd Mikus
Journal:  Clin Pharmacol Ther       Date:  2003-05       Impact factor: 6.875

Review 10.  Clinical relevance of P-glycoprotein in drug therapy.

Authors:  Jiunn H Lin; Masayo Yamazaki
Journal:  Drug Metab Rev       Date:  2003-11       Impact factor: 4.518
View more
  6 in total

Review 1.  Impact of osmotically active excipients on bioavailability and bioequivalence of BCS class III drugs.

Authors:  Mei-Ling Chen; Nakissa Sadrieh; Lawrence Yu
Journal:  AAPS J       Date:  2013-07-19       Impact factor: 4.009

Review 2.  Clinical Implications of P-Glycoprotein Modulation in Drug-Drug Interactions.

Authors:  Marie Lund; Tonny Studsgaard Petersen; Kim Peder Dalhoff
Journal:  Drugs       Date:  2017-05       Impact factor: 9.546

3.  Analysis of Complex Absorption After Multiple Dosing: Application to the Interaction Between the P-glycoprotein Substrate Talinolol and Rifampicin.

Authors:  Michael Weiss; David Z D'Argenio; Werner Siegmund
Journal:  Pharm Res       Date:  2022-09-26       Impact factor: 4.580

4.  Sex- and Gender-Based Pharmacological Response to Drugs.

Authors:  Franck Mauvais-Jarvis; Heiner K Berthold; Ilaria Campesi; Juan-Jesus Carrero; Santosh Dakal; Flavia Franconi; Ioanna Gouni-Berthold; Mark L Heiman; Alexandra Kautzky-Willer; Sabra L Klein; Anne Murphy; Vera Regitz-Zagrosek; Karen Reue; Joshua B Rubin
Journal:  Pharmacol Rev       Date:  2021-04       Impact factor: 25.468

5.  Pharmacokinetic Drug-Drug Interaction Study of Omecamtiv Mecarbil With Amiodarone and Digoxin in Healthy Subjects.

Authors:  Ashit Trivedi; Winnie Sohn; Cheng-Pang Hsu; Pegah Jafarinasabian; Hanze Zhang; Shauna Hutton; Stephen Flach; Siddique Abbasi; Sandeep Dutta; Edward Lee
Journal:  Clin Pharmacol Drug Dev       Date:  2021-10-11

Review 6.  Are antibacterial effects of non-antibiotic drugs random or purposeful because of a common evolutionary origin of bacterial and mammalian targets?

Authors:  Axel Dalhoff
Journal:  Infection       Date:  2020-12-15       Impact factor: 3.553
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.